Drug intelligence / Profile preview

SL1-38

Development stage: Preclinical
Lead developer: Dominican University of California
Modality: Small Molecules
Administration: Parenteral

Overview

SL1-38 is a second-generation diarylthiourea analog of the flexible heteroarotinoid (flex-het) SHetA2. It was designed to have a lower lipophilicity (LogP) than SHetA2 to improve its clinical utility. SL1-38 has demonstrated effective anti-growth and anti-proliferative activities against estrogen receptor (ER)-negative breast cancer cell lines (such as MDA-MB-231, MDA-MB-453, and MDA-MB-468) at micromolar concentrations. Its mechanism of action involves the down-regulation of key cell cycle regulators, including cyclin A, cyclin B, cyclin D1, cyclin E, and CDK2, which leads to the blockade of S-phase progression.

Other names: 1-(3-chloro-4-methylphenyl)-3-(4-nitrophenyl)thiourea

Targets

CCNA2 (Cyclin A2)CCNE1 (Cyclin E1)CDK2 (Cyclin-dependent kinase 2)

Beyond the preview

Go deeper on SL1-38.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SL1-38.

Explore the full profile